Ray Therapeutics
Biotechnology, San Francisco, California, United States, 1-10 Employees
Who is RAY THERAPEUTICS
Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly ...
Read More
-
Headquarters: San Francisco, California, United States
-
Date Founded: 2021
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from RAY THERAPEUTICS
Ray Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ray Therapeutics
Answer: Ray Therapeutics's headquarters are located at San Francisco, California, United States
Answer: Ray Therapeutics's official website is https://raytherapeutics.com
Answer: Ray Therapeutics's revenue is Under $1 Million
Answer: Ray Therapeutics has 1-10 employees
Answer: Ray Therapeutics is in Biotechnology
Answer: Ray Therapeutics contact info: Phone number: Website: https://raytherapeutics.com
Answer: Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field. RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month